AAPG vs ZYBT
Ascentage Pharma Group International and Zhengye Biotechnology Holding Ltd., side by side — 3 fiscal years reported in CNY, drawn from SEC filings.
Most recent reported year
| Metric | AAPG | ZYBT |
|---|---|---|
| Revenue | CNY 980.6M | CNY 116.4M |
| Net income | CNY -405.4M | CNY -69.8M |
| Gross margin | 97.0% | 20.5% |
| Net margin | −41.4% | −71.3% |
| Return on equity | −249.8% | −26.1% |
| Diluted EPS | −CNY 1.34 | · |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | CNY -135.6M | CNY 12.3M |
| Equity | CNY 264.2M | CNY 249.8M |
| Net debt / equity | 2.93× | −0.16× |
| Current ratio | 1.26× | 1.14× |
| Revenue CAGR 5y | · | · |
| Profit CAGR 5y | · | · |
AAPG bills 8.4× the revenue of ZYBT, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
3 years side by side
| Fiscal year | AAPG | ZYBT |
|---|---|---|
| FY2024 | CNY 980.6M | CNY 186.4M |
| FY2023 | CNY 222.0M | CNY 211.7M |
| FY2022 | CNY 209.7M | CNY 260.3M |
Bottom line
| Fiscal year | AAPG | ZYBT |
|---|---|---|
| FY2024 | CNY -405.4M | CNY 11.3M |
| FY2023 | CNY -925.6M | CNY 31.5M |
| FY2022 | CNY -882.9M | CNY 46.7M |
Standard deviation, each side
AAPG's net margin has been more volatile than ZYBT's over the 3 comparable fiscal years — 178.0 percentage points of standard deviation against 6.0.
3 of 4 comparable fiscal years — a year missing data on either side is not counted.
Year by year
ZYBT led in net margin in every one of the 3 comparable fiscal years — a structural lead, not a recent swing.
3 of 4 comparable fiscal years — a year missing data on either side is not counted.